WATERTOWN, Mass.--(BUSINESS WIRE)--Panacos Pharmaceuticals, Inc. (NASDAQ: PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that the Company and the US Food and Drug Administration (FDA) have agreed to a revised trial design for the Company’s Phase 2b clinical study of bevirimat (PA-457), the first-in-class maturation inhibitor for the treatment of HIV infection. The first cohort in this study was completed in December, 2006 and confirmed the antiviral activity of bevirimat shown in previous studies and extended it to HIV patients failing therapy due to antiretroviral resistance. However, the prototype tablet formulation used in that cohort resulted in bevirimat plasma concentrations that were lower than anticipated.
